SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Jay Fram

248

Biogen

BIIB

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.

Looking for leads, investment insights, or competitive intelligence?

CEO

Michel Vounatsos

CEO Title

Chief Executive Officer & Director

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Cambridge, MA

Years on Fortune 500 List

8

Employees

7,400

Profile provided by S&P Global.
Biogen is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$11,4496.4%
Profits ($M)$3,702.84.4%
Assets ($M)$22,877
Total Stockholder Equity ($M)$12,140.1
Market Value — as of March 31, 2017 ($M)$59,046
Profit Ratios
Profit as % of Revenues32.3%
Profits as % of Assets16.2%
Profits as % of Stockholder Equity30.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)16.93
EPS % Change (from 2015)10.4%
EPS % Change (5 year annual rate)27.4%
EPS % Change (10 year annual rate)39.0%
Total Return
Total Return to Investors (2016)-7.4%
Total Return to Investors (5 year, annualized)20.8%
Total Return to Investors (10 year, annualized)19.1%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Biogen

Could a New Immunotherapy Medical Approach Break the Alzheimer's Drug Curse?

AbbVie and Alector hope to apply immunotherapy to dementia and Alzheimer's.

Read More →
Goldman Sachs Bet on Biogen's Potential Landmark Alzheimer's Drug Props Up Stock

Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.

Read More →
Do You Really Want to Love Your Medicines?

Far-fetched but pharma marketers are giving it a try

Read More →